Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1809 results
March 2020
-
Statement
Novartis provides update on use and safety of Beovu® in patients with wet AMD
-
Story
The data42 program shows Novartis’ intent to go big on data and digital
Novartis is betting on both human inquisitiveness and computer expertise to harness the wealth of its digital research and development platform, data42.
-
Story Discovery
Meet Achim, leading the data42 program
The recently appointed leader of the Novartis’ digital research and development platform data42 is a strong believer that data and digital technologies will change the path of medical science.
-
Statement
Novartis coronavirus update (supply chain, response measures, EFPIA R&D call)
-
Story People and Culture
Novartis Social Business Careers: improving health in lower income countries
This is the story of how three Novartis colleagues took a career decision to improve health in lower income countries.
-
Featured News
International Women’s Day 2020
To celebrate International Women’s Day we explore how an inclusive environment that values unique and curious minds helps everyone be inspired to innovate every day.
-
Story From Our Labs
Advancing medicine through collaboration
In Wendi Yajnik’s quest to find new technologies that could transform medicine, relationships are priority No. 1.
-
Story Discovery
Clinical trial comes together in weeks to address coronavirus
Researchers race to put hydroxychloroquine to the test in a large study.
-
Media Release
International research partnership and EDCTP to invest €44m in next-generation antimalarials to combat drug-resistant malaria in Africa
EDCTP grants the PAMAfrica research consortium €21.9 million over a 5 year period; MMV, Novartis and other partners will provide an additional €22 million. The PAMAfrica consortium brings… -
Key Release
Sandoz Resolves Generic Drug Antitrust Investigation in the U.S.
Princeton, New Jersey, March 2, 2020 – Sandoz Inc. has reached a resolution with the U.S. Department of Justice (DOJ) Antitrust Division concerning the Department’s more than three-year-long…
February 2020
-
Key Release
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
Shareholders approve 23rd consecutive dividend increase to CHF 2.95 (+4%) per share for 2019; representing a 3.5%1 yield and approximately 54% payout of free cash flow Shareholders confirm Dr.… -
Key Release
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration à l’Assemblée générale annuelle
Les actionnaires approuvent la 23e augmentation consécutive du dividende qui passe à CHF 2.95 (+4%) par action pour l’année 2019, soit un rendement de 3,5%1 et une distribution du free cash-flow…